Cannabidiol prevents Alzheimer’s-like cognitive decline in new rat study

A compound found in cannabis may help protect the brain from early memory and social problems linked to Alzheimer’s disease. A new animal study published in Neuropsychopharmacology found that cannabidiol prevented cognitive decline in rats by reducing brain inflammation and activating key brain receptors.

Alzheimer’s disease is a progressive brain disorder best known for causing memory loss, but it also affects thinking, decision-making, and social engagement. Scientists increasingly recognize that inflammation in the brain plays a major role in driving these symptoms, especially in the early stages of the disease.

Cannabidiol is a chemical compound extracted from the cannabis plant that does not cause a “high.” In recent years, it has gained attention for its potential anti-inflammatory and neuroprotective properties. While cannabidiol is already used in some medical treatments, its possible role in preventing or slowing Alzheimer’s disease remains under investigation.

Roni Shira Toledano and Irit Akirav from the University of Haifa, Israel, wanted to explore whether cannabidiol could stop Alzheimer-like symptoms from developing in the first place, rather than trying to reverse damage after it occurs. They were particularly interested in the role of type 1 cannabinoid receptors, which are found throughout the brain and are involved in memory, learning, and inflammation control.

To test this, the scientists conducted experiments using male rats. The rats were injected with a substance known as streptozotocin, which triggers brain changes similar to those seen in Alzheimer’s disease, including amyloid β-protein accumulation and tau phosphorylation. Some of the rats then received regular doses of cannabidiol, while others did not.

Free daily newsletter

The researchers monitored the animals’ behavior using standard tests of memory, learning, and social interaction. They also examined brain tissue to measure levels of inflammation and to determine whether type 1 cannabinoid receptors were involved in cannabidiol’s effects.

The results revealed that the rats that did not receive cannabidiol showed clear memory problems and reduced interest in social interaction—behaviors commonly seen in Alzheimer’s disease. In contrast, rats treated with cannabidiol performed normally on memory tasks and continued to interact socially with other rats.

Brain analysis revealed that cannabidiol-treated rats had lower levels of inflammation compared to untreated rats. When researchers blocked type 1 cannabinoid receptors using a different substance, many of cannabidiol’s protective effects disappeared, suggesting that these receptors play an important role in how cannabidiol protects the brain.

The findings suggest that cannabidiol may help prevent cognitive and social decline by calming inflammation in the brain and supporting normal brain signaling. The researchers emphasize that cannabidiol did not simply mask symptoms, but appeared to prevent damage from developing in the first place.

“As current Alzheimer’s disease treatments are limited, our study highlights cannabidiol as a promising candidate, demonstrating for the first time that a low dose can prevent behavioral and molecular deficits in a rodent model of [the disease],” the authors concluded.

However, the study has important limitations. It was conducted only in male rats, and animal models do not perfectly replicate human Alzheimer’s disease. Additionally, the study focused on early-stage changes rather than long-term disease progression.

The study, “Cannabidiol prevents cognitive and social deficits in a male rat model of Alzheimer’s disease through CB1 activation and inflammation modulation,” was authored by Roni Shira Toledano and Irit Akirav.